Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors. What happened to Telomir Pharmaceuticals (TELO) today? On Friday, November 21, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a Miami‑based preclinical biotech focused on small‑molecule therapies for cancer, aging and age‑related disease, released a new press release highlighting fresh in‑vitro data in human leukemia cells. FinanzNachrichten.de+1 In parallel, investors digested a separate corporate governance update: the company disclosed that board member Dr. Craig Eagle has stepped down, effective November 14, 2025,